Analysts have slightly raised their price target for Smith & Nephew, increasing it from $14.21 to $14.23 due to minor adjustments to key valuation metrics and a modest uptick in forecasted discount rates.
What's in the News
- New study shows Smith & Nephew's PICO sNPWT device significantly outperforms competitors in reducing wound complications, hospital stays, and healthcare costs in orthopedic and cardiovascular surgeries (Key Developments).
- Sectra has expanded its 3D pre-operative planning templates to include Smith & Nephew's solutions, which is improving efficiency and clinical outcomes in orthopedic trauma surgery (Key Developments).
- Recent clinical evidence and expanded market indications demonstrate strong results for Smith & Nephew's REGENETEN Bioinductive Implant in rotator cuff and ligament repair, resulting in lower re-tear rates and improved healing (Key Developments).
- Smith & Nephew has launched the CENTRIO PRP System, a new wound care technology designed to support healing in chronic and complex wounds, now available in the United States (Key Developments).
- The company has commenced a share repurchase program and announced an approved interim dividend for 2025. Financial guidance remains unchanged (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly, moving from £14.21 to £14.23 per share.
- Discount Rate increased modestly from 8.05% to 8.12%.
- Revenue Growth forecast is virtually unchanged, remaining steady at approximately 5.47%.
- Net Profit Margin remains stable at roughly 13.13%.
- Future P/E ratio has edged up from 22.79x to 22.91x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.